What is the 13F Pro Quality Score for KALV?

13F Pro ranks KalVista Pharmaceuticals, Inc. (KALV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KALV's current score at https://13fpro.ai/company/KALV (free sign-up required for the full ranking).

Where does 13F Pro source KALV data?

All KalVista Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. KalVista Pharmaceuticals, Inc. files with the SEC under CIK 1348911. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KALV in?

KalVista Pharmaceuticals, Inc. (KALV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is KALV research updated on 13F Pro?

KALV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

KalVista Pharmaceuticals, Inc.(KALV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1348911 KALV stock profile & AI dashboard →

13F Pro Quality Score

12.8/100

Rank #2,781 of 2,854 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

6.2/100

Profitability

6.4/100

Balance Sheet

5.3/100

Earnings Quality

27.3/100

Free Cash Flow

6.5/100

Institutional Flow

42.2/100

Revenue Scale

15.9/100

Dilution Risk

7.3/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why KALV Scores 13/100

exact factor attribution · 2026-05-27

KALV's composite is held back by revenue growth and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

-0.4 pts

42th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-2.1 pts

7th pct

Earnings quality

-2.3 pts

27th pct

Capital efficiency

-4.5 pts

5th pct

Scale

-5.1 pts

16th pct

Free cash flow

-6.5 pts

7th pct

Profitability

-6.5 pts

6th pct

Revenue growth

-8.8 pts

6th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

KALV Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for KalVista Pharmaceuticals, Inc. (KALV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KALV at 12.8/100 on a 32-signal composite quality model, placing it at rank #2,781 of 2,854 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (5.3) and revenue growth (6.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), KalVista Pharmaceuticals, Inc. reports quarterly revenue of $40.9M, net income of $-23.5M, free cash flow of $-14.6M. Top institutional holders of KALV by reported 13-F value include VR Adviser, Frazier Life Sciences Management, L.P., SUVRETTA CAPITAL MANAGEMENT, based on the most recent SEC filings. KALV trades on the Nasdaq exchange and files with the SEC under CIK 1348911. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KALV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KalVista Pharmaceuticals, Inc. directly from SEC EDGAR. KalVista Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 13 and 26 since 2021, currently 12.8 — a declining long-term trajectory across 41 quarterly and live scoring snapshots.

✦

Fun facts about KalVista Pharmaceuticals, Inc.

Quirks, history, and lore behind KALV — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · with a dual presence in the United Kingdom and the United States.
2
The Numbers
A small-cap biotech with no product revenue yet — it runs on cash reserves and grants while advancing a pipeline that fits on a single PowerPoint slide.
3
The History
Founded in the 2010s, it was built around a then-underexplored enzyme target and has spent years advancing compounds from discovery through clinical trials.
4
The Secret
Its entire pipeline orbits a single enzyme: plasma kallikrein, which plays a starring role in conditions driven by uncontrolled swelling and fluid leakage.
5
The Lore
Its lead programs target hereditary angioedema — a rare, life-threatening swelling disorder — and diabetic macular edema, a leading cause of vision loss.
6
The Giveaway
The name is literally a portmanteau of kallikrein and Vista — a company whose ticker, pipeline, and identity all shout one enzyme louder than anything else.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$40.9M

Net Income

Q1 2026

$-23.5M

Free Cash Flow

Q1 2026

$-14.6M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

—FY 2026

FY23 —FY24 $50.0MFY25 —FY26 —

Net Income

—FY 2026

FY23 $-92.9MFY24 $-126.6MFY25 $-183.4MFY26 —

Operating Income

—FY 2026

FY23 $-110.9MFY24 $-140.4MFY25 $-188.0MFY26 —

EPS (Diluted)

—FY 2026

FY23 $-3.33FY24 $-3.44FY25 $-3.69FY26 —

Total Assets

+31.2% YoY

$328.9MFY 2026

FY23 $183.2MFY24 $235.4MFY25 $250.8MFY26 $328.9M

Total Debt

$172.2MFY 2026

FY23 —FY24 —FY25 —FY26 $172.2M

Op. Cash Flow

—FY 2026

FY23 $-75.3MFY24 $-89.2MFY25 $-152.9MFY26 —

Free Cash Flow

—FY 2026

FY23 $-76.5MFY24 $-89.3MFY25 $-153.3MFY26 —

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	—	—	$50.0M	—	—	—
Net Income	—	$-183.4M -44.9%	$-126.6M -36.3%	$-92.9M -12.8%	$-82.3M -78.1%	$-46.2M
Operating Income	—	$-188.0M -33.9%	$-140.4M -26.7%	$-110.9M -14.8%	$-96.6M -66.8%	$-57.9M
EPS (Diluted)	—	$-3.69 -7.3%	$-3.44 -3.3%	$-3.33 +0.9%	$-3.36 -38.8%	$-2.42
Total Assets	$328.9M +31.2%	$250.8M +6.5%	$235.4M +28.5%	$183.2M -10.1%	$203.9M -25.0%	$272.0M
Total Debt	$172.2M	—	—	—	—	—
Operating Cash Flow	—	$-152.9M -71.4%	$-89.2M -18.6%	$-75.3M +3.7%	$-78.1M -159.0%	$-30.2M
Free Cash Flow	—	$-153.3M -71.8%	$-89.3M -16.8%	$-76.5M +3.3%	$-79.1M -161.3%	$-30.3M

Get alerted when KALV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for KalVista Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KALV

VR Adviser, LLC
$130.3M6,474,485 sh
Frazier Life Sciences Management, L.P.
$99.9M4,961,108 sh
SUVRETTA CAPITAL MANAGEMENT, LLC
$96.0M4,768,712 sh
TANG CAPITAL MANAGEMENT LLC
$92.1M4,573,530 sh
BlackRock, Inc.
$76.4M3,795,897 sh
SILVERARC CAPITAL MANAGEMENT, LLC
$57.9M2,876,407 sh
Capital World Investors
$56.5M2,808,583 sh
Point72 Asset Management, L.P.
$43.0M2,136,940 sh
STATE STREET CORP
$39.4M1,955,844 sh
MILLENNIUM MANAGEMENT LLC
$38.5M1,912,146 sh

Fund	Value	Shares
VR Adviser, LLC	$130.3M	6,474,485
Frazier Life Sciences Management, L.P.	$99.9M	4,961,108
SUVRETTA CAPITAL MANAGEMENT, LLC	$96.0M	4,768,712
TANG CAPITAL MANAGEMENT LLC	$92.1M	4,573,530
BlackRock, Inc.	$76.4M	3,795,897
SILVERARC CAPITAL MANAGEMENT, LLC	$57.9M	2,876,407
Capital World Investors	$56.5M	2,808,583
Point72 Asset Management, L.P.	$43.0M	2,136,940
STATE STREET CORP	$39.4M	1,955,844
MILLENNIUM MANAGEMENT LLC	$38.5M	1,912,146

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KALV on your watchlist

Track score changes the day KalVista Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KALV a good stock to buy?

13F Pro's AI-powered analysis of KalVista Pharmaceuticals, Inc. (KALV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KALV are available on the KALV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KALV is classified as a small company.

Which hedge funds own KALV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KALV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of KalVista Pharmaceuticals, Inc.'s investment landscape.